期刊
DRUG DISCOVERY TODAY
卷 13, 期 17-18, 页码 778-784出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2008.05.011
关键词
-
资金
- NHLBI NIH HHS [P01 HL091799, P01 HL091799-010004] Funding Source: Medline
Cardiotoxicity of some targeted therapeutics, including monoclonal antibodies and small-molecule inhibitors, is a reality. Herein we will examine why it occurs, focusing on molecular mechanisms to better understand the issue. We will also examine how big the problem is and, more importantly, how big it may become in the future. We will review models for detecting cardiotoxicity in the preclinical phase. We will also focus on two key areas that drive cardiotoxicity: multitargeting and the inherent lack of selectivity of ATP-competitive antagonists. Finally, we will examine the issue of reversibility and discuss possible approaches to keeping patients on therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据